A little background, because cancer biology enjoys introducing characters as if it were a Victorian novel. STK11, also called LKB1, is a tumor suppressor gene. When it works, it helps cells manage energy stress and keep themselves reasonably civilized. When it is lost or mutated, some lung tumors become more aggressive and, just to keep life interesting, more resistant to immunotherapy.[2,3]
That resistance has frustrated clinicians for years. Immune checkpoint drugs such as anti-PD-1 or anti-PD-L1 are supposed to take the brakes off your immune system. But STK11-mutant tumors often create a "cold" tumor microenvironment - fewer helpful T cells, more suppressive immune cells, and generally the atmosphere of a nightclub where security has been paid by the wrong guy.[2-5]
CRTC2 enters here. It is a co-activator for CREB, a transcription factor that helps turn genes on. In plain English, CRTC2 helps deliver instructions from the nucleus. In this 2026 PNAS study, the authors found that CRTC2 is a key control point for how STK11-mutant tumors shape the immune environment around them.[1]
What The New Study Actually Did
The central result is pleasingly direct. When the researchers deleted CRTC2 in STK11-deficient tumor models, the immune landscape changed and the tumors became sensitive again to anti-PD-1 treatment.[1]
That matters because the problem in these cancers is not simply that tumor cells grow fast. Plenty of tumors do that. The trickier problem is that STK11-mutant tumors seem to recruit the wrong immune company and send the useful troops to the wrong address. The paper argues that CRTC2 helps run those cell-extrinsic effects - meaning it influences how the tumor behaves toward neighboring immune cells, not just how it behaves internally.[1]
Even more interesting, the authors report that it was enough to disrupt the CRTC2-CREB interaction to restore immunotherapy sensitivity.[1] That is the sort of result drug developers circle in red ink. If you can break a specific protein partnership rather than bulldozing an entire pathway, you may get something both more effective and less chaotic. Biology, like home renovation, tends to go better when you do not knock down every wall.
Why People In Lung Cancer Are Paying Attention
This paper did not appear out of nowhere. Over the last few years, the field has been building a case that STK11 and its frequent traveling companions, especially KEAP1 and KRAS, help define a harder-to-treat subtype of NSCLC.[3-5]
A 2024 Nature study showed that patients with STK11 and/or KEAP1 alterations may benefit more from dual checkpoint blockade with CTLA4 plus PD-(L)1 inhibition than from PD-(L)1 blockade alone.[5] Recent reviews and clinical perspective papers have also argued that these mutations should be taken seriously when interpreting genomic testing in advanced NSCLC, not filed away as decorative footnotes beneath the EGFR and ALK headlines.[3,4] Fair enough. The genome report is not wallpaper.
So this new CRTC2 paper fits a bigger pattern. The field is moving from saying, "these tumors resist immunotherapy," to asking, "fine, but exactly which lever can we pull to change that?"[1,3-5]
The Part Where We Keep Our Shoes On The Ground
Before anyone starts planning a victory parade, this is not a ready-for-clinic cure. The study is strong mechanistically, but it is still preclinical. No one reading this should assume that a patient can walk into an infusion center next Tuesday and ask for a CRTC2 inhibitor with a side of optimism.[1]
There are real challenges ahead. CRTC2 is involved in broader biology beyond cancer, so specificity and safety will matter. STK11-mutant lung cancers are also heterogeneous, because cancer never misses a chance to be annoying. Some carry KRAS, some KEAP1, some TP53, and each combination can change the immune ecosystem and treatment response.[3,5]
Still, if these findings hold up, the real-world impact could be substantial. Patients with STK11-mutant NSCLC often have fewer good immunotherapy options. A strategy that re-opens the door to PD-1 blockade could turn a biologically "cold" tumor into one the immune system can finally recognize and attack.[1]
That would be no small thing. After decades of cancer research, one learns humility. Every era has had its miracle molecule. I remember when interferon was going to tidy up the whole mess. It did not. But this study has the kind of logic I trust: identify the sabotage, trace the wiring, and snip the right connection.
References
-
Robay D, Ackermann O, Laborde L, et al. Targeting CRTC2 reverses STK11 mutant NSCLC tumor resistance to immunotherapy. Proc Natl Acad Sci U S A. 2026;123(17):e2508762123. DOI: https://doi.org/10.1073/pnas.2508762123. PMCID: https://pmc.ncbi.nlm.nih.gov/articles/PMC13123801/
-
Pons-Tostivint E, Lugat A, Fonteneau J-F, Denis MG, Bennouna J. STK11/LKB1 Modulation of the Immune Response in Lung Cancer: From Biology to Therapeutic Impact. Cells. 2021;10(11):3129. DOI: https://doi.org/10.3390/cells10113129
-
Knetki-Wroblewska M, Wojas-Krawczyk K, Krawczyk P, Krzakowski M. Emerging insights into STK11, KEAP1 and KRAS mutations: implications for immunotherapy in patients with advanced non-small cell lung cancer. Transl Lung Cancer Res. 2024;13(12):3718-3730. DOI: https://doi.org/10.21037/tlcr-24-552. PMCID: https://pmc.ncbi.nlm.nih.gov/articles/PMC11736579/
-
Spira A, Drilon A, Lara PN Jr, et al. Clinical perspectives on the value of testing for STK11 and KEAP1 mutations in advanced NSCLC. Front Oncol. 2024. DOI: https://doi.org/10.3389/fonc.2024.1459737. PMCID: https://pmc.ncbi.nlm.nih.gov/articles/PMC11655323/
-
Arbour KC, Rizvi H, Plodkowski AJ, et al. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024;635:462-471. DOI: https://doi.org/10.1038/s41586-024-07943-7
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.